CSIMarket Company Name, Ticker, Suppliers, else..
 
Lava Therapeutics Nv  (NASDAQ: LVTX)
 
Price: $1.7400 $-0.07 -3.867%
Day's High: $1.82 Week Perf: 5.45 %
Day's Low: $ 1.62 30 Day Perf: 6.75 %
Volume (M): 285,500 52 Wk High: $ 1.83
Volume (M$): $ 497 52 Wk Avg: $1.61
Open: $1.81 52 Wk Low: $1.44



 Market Capitalization (Millions $) 47
 Shares Outstanding (Millions) 27
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -23
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a clinical-stage immuno-oncology firm developing a proprietary Gammabody® platform of bispecific gamma delta (γδ) T cell engagers for cancer treatment. Their approach involves creating off-the-shelf bispecific antibodies that utilize γδ T cells to induce an anti-tumor immune response.


   Company Address: Yalelaan 62 Utrecht 3584 NL
   Company Phone Number: 85 016 3100   Stock Exchange / Ticker: NASDAQ LVTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Evolving Cancer Treatment: Pfizer Achieves Clinical Milestone in Breakthrough Drug PF-08046052

Published Tue, Mar 5 2024 12:30 PM UTC

Clinical Milestone Achieved by Pfizer in Phase 1 Study of PF-08046052 - A Potential Breakthrough in Cancer TreatmentIn the ever-evolving field of medical research, groundbreaking advancements are essential to combatting diseases and improving patient outcomes. One such milestone has recently been achieved by global pharmaceutical giant Pfizer in the clinical development of P...
Partnership

A Revolutionary Collaboration: LAVA Therapeutics and Merck Join Forces to Revolutionize mCRPC Treatment

Published Thu, Jan 25 2024 12:00 PM UTC

LAVA Therapeutics and Merck Join Forces to Revolutionize mCRPC Treatment: A Promising Collaboration to Explore Combination TherapyIn a major stride towards advancing treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), LAVA Therapeutics recently announced a groundbreaking collaboration with Merck & Co., Inc., based in Rahway, New Jerse...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 3.69
PEG (TTM) -

Financial Strength Current
Quick Ratio 23.48
Working Capital Ratio 24.01
Leverage Ratio (MRQ) 3.09
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.86 $
Revenues (TTM) -
Cash Flow (TTM) 0.09 $
Cash 3.69 $
Book Value 0.47 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.